MNKD Share Price

Open 0.50 Change Price %
High 0.61 1 Day 0.07 14.58
Low 0.48 1 Week 0.00 0.00
Close 0.55 1 Month 0.13 30.95
Volume 9046347 1 Year -1.48 -72.91
52 Week High 2.24
52 Week Low 0.00
MNKD Important Levels
Resistance 2 0.67
Resistance 1 0.62
Pivot 0.55
Support 1 0.48
Support 2 0.43
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

MannKind Corporation (NASDAQ: MNKD)

MNKD Technical Analysis 4
As on 2nd Dec 2016 MNKD Share Price closed @ 0.55 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.99 & Sell for SHORT-TERM with Stoploss of 0.56 we also expect STOCK to react on Following IMPORTANT LEVELS.
MNKD Target for December
1st Target up-side 0.62
2nd Target up-side 0.72
3rd Target up-side 0.82
1st Target down-side 0.32
2nd Target down-side 0.22
3rd Target down-side 0.12
MNKD Other Details
Segment EQ
Market Capital 405527936.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.mannkindcorp.com
MNKD Address
MNKD
28903 North Avenue Paine
Valencia, CA 91355
United States
Phone: 661-775-5300
Interactive Technical Analysis Chart MannKind Corporation ( MNKD NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on MannKind Corporation
MNKD Business Profile
MannKind Corporation (MannKind) is a development-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. The Company�s product candidate, AFREZZA (insulin human) inhalation powder, is insulin that is in late-stage clinical investigation for the treatment of adults with type I or type II diabetes for the control of hyperglycemia. The AFREZZA inhalation powder is centered on a class of potential of hydrogen (pH)-sensitive organic molecules. AFREZZA utilizes its Technosphere formulation technology. As of December 31, 2011, MannKind had not generated any product revenues. As of December 31, 2011, the AFREZZA clinical program had involved 61 different studies of AFREZZA and over 5,600 adult patients.